1. Home
  2. DFNS vs EVAX Comparison

DFNS vs EVAX Comparison

Compare DFNS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFNS

T3 Defense Inc. Common Stock

N/A

Current Price

$37.95

Market Cap

27.2M

ML Signal

N/A

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$3.10

Market Cap

23.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFNS
EVAX
Founded
2013
2008
Country
United States
Denmark
Employees
15
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
23.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DFNS
EVAX
Price
$37.95
$3.10
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
23.3M
12.0K
Earning Date
04-09-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$2.52
52 Week High
$91.00
$12.15

Technical Indicators

Market Signals
Indicator
DFNS
EVAX
Relative Strength Index (RSI) 58.90 46.42
Support Level $0.30 $2.97
Resistance Level $91.00 $3.61
Average True Range (ATR) 13.65 0.13
MACD 3.10 0.03
Stochastic Oscillator 49.58 59.21

Price Performance

Historical Comparison
DFNS
EVAX

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: